MIMETAS develops methods for testing medicine in microscopic human tissues in microfluidic chips, so-called ‘organs on a chip’. The purpose of these tests is to better predict the effects of medicine on people in a lab.
+31 (0)85 888 31 61, www.mimetas.com
Since 2010, Paul Vulto (left) and Jos Joore (right) have been working on the foundation of MIMETAS. In 2013, the OrganoPlate was introduced on the market and MIMETAS signed its first agreement with a customer in the pharmaceutical industry.
MIMETAS develops methods for testing medicine in microscopically small human tissues in microfluidic chips, so-called ‘organs on a chip’. The microfluidic chips are called ‘OrganoPlates’. The purpose of these tests is to better predict the effects of medicine on people in labs. This allows expensive clinical research on patients to be applied more efficiently. Not only does this save time, but also hundreds of millions of dollars on the development of new medicine.
MIMETAS works with most of the largest pharmaceutical companies to develop improved models.
MIMETAS develops models for a large number of organs and tissues. The team has made enormous progress in the development of kidney tissue, nerve cell, and blood vessel models. In addition, in 2015, an OrganoPlates factory will become operational in Twente, which is unique in the world. Here, MIMETAS produces a large number of OrganoPlates, at a low-cost and tailored for specific applications.
MIMETAS is a technological leader in the field of fast and easy deployment of organ and tissue models. In the upcoming years, MIMETAS aims to achieve further business growth and technical development of these models.
MIMETAS consists of a team of highly skilled, enthusiastic biologists and engineers who work together on the technological and biological development of the company’s products. Paul Vulto and Jos Joore are in charge of the management. Paul Vulto is an engineer, expert in the ‘organs on a chip’ field, and inventor of the microfluidic technology in OrganoPlates. Jos Joore is a biologist and experienced manager of biotechnological companies.
Why KIKK capital?
Jos: “KIKK Capital (fund: ZIF) has a pragmatic approach to investments; hard work, smart ideas, and the right people in the right place are key. This fits in well with the working methods of MIMETAS, where we always focus on content, results, and job satisfaction.”
Added value of KIKK CAPITAL
Jos: “The down-to-earth fund management works with a unique network of managers of Dutch and international top companies. Access to this wealth of experience is a unique opportunity for a young high-tech company like MIMETAS.”